MS vs PFE: Which Is the Better Buy?
Side-by-side comparison of Morgan Stanley and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-05.
Morgan Stanley · Financial Services
$189.30
+45.0% upside to fair value
Grade C
High Quality
VS
Pfizer Inc. · Healthcare
$26.33
+28.6% upside to fair value
Grade B
QuantHub Verdict
MS has more upside to fair value
(+45.0%).
MS trades at a lower forward P/E
(16.4x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MS |
PFE |
| Current Price |
$189.30 |
$26.33 |
| Fair Value Estimate |
$274.49 |
$33.85 |
| Upside to Fair Value |
+45.0%
|
+28.6%
|
| Market Cap |
$300.6B |
$149.8B |
| Forward P/E |
16.4x
|
19.3x
|
| EV / EBITDA |
24.4x
|
12.9x
|
| Price / Sales |
2.5x
|
2.4x
|
| Price / FCF |
-16.8x
|
16.5x
|
| Revenue Growth YoY |
+18.8%
|
-1.2%
|
| Gross Margin |
58.0%
|
70.3%
|
| Operating Margin |
19.5%
|
24.7%
|
| Return on Equity |
16.7%
|
8.7%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
—
|
6.06%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Morgan Stanley is a leading global financial services firm operating in Institutional Securities, Wealth Management, and Investment Management. The company benefits from a durable competitive moat supported by its systemically important status, diversified revenue streams, and strong management with a 36-year veteran CEO. Despite solid fundamentals including 14.2% revenue growth in 2025 and 16.7%…
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
Accumulation Zones
| Metric |
MS |
PFE |
| Zone Low |
$205.87 |
$25.39 |
| Zone High |
$233.32 |
$28.77 |
| In Buy Zone? |
Yes
|
Yes
|